PP 1 (SKU: A8215): Selective Src Family Tyrosine Kinase Inhibitor for Mechanistic Cancer and Immunology Research

Executive Summary: PP 1 (SKU: A8215) is a chemically defined, nanomolar-range inhibitor of Src family tyrosine kinases, with high selectivity for Lck (IC50: 5 nM) and Fyn (IC50: 6 nM), and demonstrated efficacy in suppressing Lyn kinase without affecting Syk kinase activity (APExBIO product page). PP 1 is widely used for dissecting T cell activation, inhibition of RET oncoprotein signaling (IC50: 80 nM), and mechanistic studies of tumor progression and metastasis (Xiao et al. 2020). The compound supports high solubility in ethanol and DMSO, is not water-soluble, and requires cold, desiccated storage. No clinical trials are reported, and off-target effects on non-Src kinases are minimal at recommended concentrations. Its application extends to in vivo and in vitro models for mapping caspase and Src kinase signaling networks in oncology and immunology.

Biological Rationale

Src family tyrosine kinases (SFKs) such as Lck, Fyn, and Lyn are non-receptor enzymes that modulate phosphorylation-dependent signaling in eukaryotic cells. These kinases regulate T cell receptor (TCR) activation, cell proliferation, motility, and survival. Aberrant SFK activity is implicated in tumor progression, metastasis, and immune dysregulation (Xiao et al. 2020). Selective inhibition of SFKs allows precise interrogation of cell signaling pathways in cancer and immunological assays. PP 1 (SKU: A8215), as manufactured by APExBIO, was developed to enable such targeted inhibition, providing a tool for high-precision mechanistic studies (APExBIO).

Mechanism of Action of PP 1 (SKU: A8215) Src family tyrosine kinase inhibitor

PP 1 is a synthetic pyrazolopyrimidine derivative, chemically designated as 1-tert-butyl-3-(4-methylphenyl)pyrazolo[3,4-d]pyrimidin-4-amine (C16H19N5, MW: 281.36). It competitively inhibits the ATP-binding site of Src family kinases. PP 1 exhibits IC50 values of 5 nM for Lck and 6 nM for Fyn, and potently suppresses Lyn kinase activity at similar concentrations (APExBIO). The compound does not inhibit Syk kinase at these doses, supporting its selectivity. In RET/PTC3-transformed cells, PP 1 suppresses RET-driven phosphorylation (IC50: 80 nM), causing phenotypic reversion and loss of oncogenic proliferation (Xiao et al. 2020).

In immune cells, PP 1 disrupts FcεRI- and Thy-1-mediated activation by blocking downstream phosphorylation events required for signaling cascades. In vivo, PP 1 reduces T cell proliferation, tyrosine phosphorylation, and modulates IL-2 gene expression, highlighting its value for dissecting T cell activation mechanisms.

Evidence & Benchmarks

• PP 1 inhibits Lck kinase activity in vitro with an IC50 of 5 nM, measured at 25°C in kinase buffer (APExBIO, product page).
• Fyn kinase activity is suppressed by PP 1 at an IC50 of 6 nM under identical buffer conditions (APExBIO, product page).
• Lyn kinase is inhibited at nanomolar concentrations, while Syk kinase activity remains unaffected up to 1 μM (APExBIO, product page).
• PP 1 suppresses RET/PTC3 oncoprotein-driven proliferation and phosphorylation with an IC50 of 80 nM in RET/PTC3-transformed cell lines (Xiao et al. 2020).
• In mouse models, PP 1 reduces T cell proliferation and tyrosine phosphorylation following antigen stimulation, validated by Western blot and cell proliferation assays (Xiao et al. 2020).
• PP 1 is insoluble in water but shows solubility ≥20.6 mg/mL in ethanol (25°C, ultrasonic assistance) and ≥7.03 mg/mL in DMSO (APExBIO, product page).
• No clinical trials have been reported for PP 1 as a therapeutic; its use is strictly as a research tool (APExBIO, product page).
• Inhibition of C-terminal Src kinase (CSK) by similar compounds has been shown to increase atrial fibrillation risk in murine models, underlining the physiological impact of Src kinase pathway modulation (Xiao et al. 2020).

For a practical workflow-oriented perspective, see Optimizing Cell Assays with PP 1 (SKU: A8215), which details experimental design with the compound; this article extends by providing structured, citation-rich benchmarks. For strategic oncology implications, Strategic Disruption of Src Family Kinases offers a translational lens, whereas the present article synthesizes recent mechanistic and selectivity data. For advanced pathway analysis, PP 1 Src Family Tyrosine Kinase Inhibitor: Unraveling Oncogenic Signaling explores non-canonical pathways; here, we focus on primary action and limitations.

Applications, Limits & Misconceptions

PP 1 (SKU: A8215) is applied in:

• Signal transduction studies to map Src kinase–dependent pathways in cancer and immune cells (Xiao et al. 2020).
• Functional analysis of T cell activation, proliferation, and IL-2 gene expression (APExBIO).
• Oncogenic RET signaling and morphological reversion studies in RET/PTC3-driven models.
• Assays for caspase signaling pathway and metastasis inhibition (PP 1 (SKU: A8215): Selective Src Family Tyrosine Kinase Inhibitor).
• Negative controls for Syk kinase activity (demonstrating selectivity).

Common Pitfalls or Misconceptions

• PP 1 is not effective against Syk kinase at standard concentrations (≤1 μM); it should not be used to probe Syk-dependent pathways (APExBIO).
• It is not soluble in aqueous buffers; improper dissolution impairs experimental reproducibility.
• PP 1 is for research use only; no clinical or therapeutic applications are validated (APExBIO).
• Prolonged storage of solutions leads to compound degradation; prepare fresh aliquots for each experiment.
• Inhibition of off-target kinases, such as CSK, may have confounding physiological effects in whole-animal studies (Xiao et al. 2020).

Workflow Integration & Parameters

PP 1 (SKU: A8215) is supplied as a solid by APExBIO and should be stored desiccated at 4°C. For cell-based assays, dissolve in DMSO (≥7.03 mg/mL) or ethanol (≥20.6 mg/mL) using ultrasonic assistance if necessary. Avoid water as the compound is insoluble. Prepare working solutions fresh before use; long-term storage of solutions is discouraged due to instability. Concentration ranges for cell signaling inhibition typically span 10–100 nM for Lck, Fyn, and Lyn, and up to 80 nM for RET/PTC3 models. Negative controls should include vehicle-only treatments (DMSO or ethanol at matching concentrations). For detailed protocol guidance, see Optimizing Cell Assays with PP 1 (SKU: A8215).

Conclusion & Outlook

PP 1 (SKU: A8215) is a validated, selective Src family tyrosine kinase inhibitor with clear utility in mechanistic cancer and immunology research (Xiao et al. 2020). Its precise selectivity profile, solubility characteristics, and robust inhibition of Lck, Fyn, and Lyn kinases distinguish it as a benchmark research compound. Limitations include absence of clinical trial data and water insolubility. Future research may address next-generation analogs with greater specificity or improved in vivo properties. For further reading on advanced applications, see PP 1 Src Family Tyrosine Kinase Inhibitor: Unraveling Oncogenic Signaling.